As expected, tumor tissues from the BTP-7-CPT group had a higher level of p-H2AX than the Scr-7-CPT group, underscoring the ability of BTP-7 to improve drug targeting to GBM (Figure 6b–d). The gene discussed is H2AX; the disease is glioblastoma.